Eveliqure Biotechnologies Gmbh
CAGE Code: 6311N
NCAGE Code: 6311N
Status: Active
Type: Commercial Supplier
Summary
Eveliqure Biotechnologies Gmbh is an Active Commercial Supplier with the Cage Code 6311N.
Address
Karl-Farkas-Gasse 22
Wien
Wien
1030
Austria
Points of Contact
No Points of Contact...
Related Information
No Related Information...
Frequently Asked Questions (FAQ) for CAGE 6311N
- What is CAGE Code 6311N?
- 6311N is the unique identifier used by NATO Organizations to reference the physical entity known as Eveliqure Biotechnologies Gmbh located at Karl-Farkas-Gasse 22, Wien, Wien, 1030, Austria.
- Who is CAGE Code 6311N?
- 6311N refers to Eveliqure Biotechnologies Gmbh located at Karl-Farkas-Gasse 22, Wien, Wien, 1030, Austria.
- Where is CAGE Code 6311N Located?
- CAGE Code 6311N is located in Wien, Austria.
Contracting History for CAGE 6311N Most Recent 25 Records
- 75N93020C00048
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- 12 Apr 2023
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,109,024.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00048
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- 29 Sep 2022
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,109,024.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00048
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- 27 Aug 2021
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,459,637.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00048
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- 29 Jun 2023
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,599,128.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00048
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- 31 Oct 2023
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,599,128.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00048
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- 6 Apr 2022
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $3,109,024.00
- Department Of Health And Human Services (Hhs)
- 75N93020C00048
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- 13 Aug 2021
- To Advance The Development Of The Shigetec Vaccine Through Cgmp Manufacturing And Release Of Additional Cgmp Lots For Use In A Series Of Phase 2 Clinical Trials.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,459,637.00
- Department Of Health And Human Services (Hhs)